Literature DB >> 1929275

Pharmacokinetics of 2',3'-dideoxyinosine in monkeys.

M X Qian1, T S Finco, A R Swagler, J M Gallo.   

Abstract

Comparison of the pharmacokinetic parameters obtained for dideoxyinosine (ddI) in monkeys with those obtained for humans indicates that the monkey is an appropriate animal model for ddI pharmacokinetics in humans. Following intravenous administration of 20 mg of ddI per kg of body weight and measurement of ddI in plasma and urine by high-performance liquid chromatography, pharmacokinetic parameters were determined by noncompartmental analysis. Total systemic clearance was 0.74 liters/h/kg, volume of distribution was 0.92 liters/kg, and the elimination half-life of ddI was 1.22 h. The pharmacokinetics of ddI in five monkeys were determined following intravenous administration of 20 mg/kg and were found to be comparable to those obtained in patients with AIDS.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1929275      PMCID： PMC284324          DOI： 10.1128/AAC.35.6.1247

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Uptake kinetics of 2',3'-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies.

Authors:  B D Anderson; B L Hoesterey; D C Baker; R E Galinsky
Journal:  J Pharmacol Exp Ther       Date:  1990-04       Impact factor: 4.030

Review 2.  Strategies for antiviral therapy in AIDS.

Authors:  H Mitsuya; S Broder
Journal:  Nature       Date:  1987 Feb 26-Mar 4       Impact factor: 49.962

3.  Inhibition of HIV reverse transcriptase by 2',3'-dideoxynucleoside triphosphates.

Authors:  M S Chen; S C Oshana
Journal:  Biochem Pharmacol       Date:  1987-12-15       Impact factor: 5.858

4.  Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.

Authors:  N R Hartman; R Yarchoan; J M Pluda; R V Thomas; K S Marczyk; S Broder; D G Johns
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

5.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

6.  Pharmacokinetics of the anti-AIDS drug 2',3'-dideoxyinosine in the rat.

Authors:  G F Ray; W D Mason; M Z Badr
Journal:  Drug Metab Dispos       Date:  1990 Sep-Oct       Impact factor: 3.922

7.  Comparative pharmacokinetics of new anti-HIV agents: 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.

Authors:  J W Russell; L J Klunk
Journal:  Biochem Pharmacol       Date:  1989-05-01       Impact factor: 5.858

8.  2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.

Authors:  R Dolin; J S Lambert; G D Morse; R C Reichman; C S Plank; J Reid; C Knupp; C McLaren; C Pettinelli
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

9.  Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.

Authors:  F T Valentine; M Seidlin; H Hochster; M Laverty
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

10.  Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.

Authors:  T P Cooley; L M Kunches; C A Saunders; C J Perkins; S L Kelley; C McLaren; R P McCaffrey; H A Liebman
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug
  10 in total
  8 in total

1.  Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Giuseppe Gumina; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

2.  Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.

Authors:  L T Martin; E Cretton-Scott; R F Schinazi; X J Zhou; H M McClure; C Mathe; G Gosselin; J L Imbach; J P Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Physiologically based pharmacokinetic models of 2',3'-dideoxyinosine.

Authors:  H J Kang; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

4.  Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.

Authors:  R F Schinazi; F D Boudinot; S S Ibrahim; C Manning; H M McClure; D C Liotta
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

5.  Pharmacokinetics of the anti-human immunodeficiency virus agent 1-(beta-D-dioxolane)thymine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Aleksandr Obikhod; David Delinsky; Janarthanan Narayanasamy; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

6.  Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.

Authors:  S Kaul; K A Dandekar
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

7.  Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine.

Authors:  Huachun Chen; S Balakrishna Pai; Selwyn J Hurwitz; Chung K Chu; Yuliya Glazkova; Harold M McClure; Mark Feitelson; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

Review 8.  Didanosine, a new antiretroviral drug. A review.

Authors:  R M Franssen; P L Meenhorst; C H Koks; J H Beijnen
Journal:  Pharm Weekbl Sci       Date:  1992-10-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.